AKBA
Akebia Therapeutics Inc
NASDAQ · Biotechnology
$1.39
+0.01 (+0.72%)
Open$1.36
Previous Close$1.38
Day High$1.40
Day Low$1.33
52W High$38.73
52W Low$22.87
Volume—
Avg Volume295.7K
Market Cap368.86M
P/E Ratio46.29
EPS$0.69
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,594.2% upside
Current
$1.39
$1.39
Target
$37.45
$37.45
$22.27
$37.45 avg
$46.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 72.37M | 65.59M | 81.13M |
| Net Income | -4,487,469 | -3,878,355 | -4,942,326 |
| Profit Margin | -6.2% | -5.9% | -6.1% |
| EBITDA | -4,274,433 | -4,128,349 | -4,627,733 |
| Free Cash Flow | -2,482,756 | -1,979,346 | -2,914,255 |
| Rev Growth | -8.8% | +11.6% | -8.0% |
| Debt/Equity | 0.21 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |